Kristen Kluska

Stock Analyst at Cantor Fitzgerald

(4.56)
# 310
Out of 4,442 analysts
124
Total ratings
47.06%
Success rate
41.14%
Average return

36 Stocks

Skye Bioscience
May 23, 2024
Initiates: Overweight
Price Target: $21
Current: $12.06
Upside: +74.13%
Fulcrum Therapeutics
May 20, 2024
Initiates: Overweight
Price Target: $23
Current: $7.21
Upside: +219.00%
89bio
May 17, 2024
Reiterates: Overweight
Price Target: $29
Current: $8.14
Upside: +256.27%
Abeona Therapeutics
May 16, 2024
Maintains: Overweight
Price Target: $28$21
Current: $4.06
Upside: +417.24%
Mereo BioPharma Group
May 16, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.95
Upside: +137.29%
Disc Medicine
May 15, 2024
Reiterates: Overweight
Price Target: $85
Current: $34.28
Upside: +147.96%
Taysha Gene Therapies
May 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.24
Upside: +116.05%
Capricor Therapeutics
May 14, 2024
Reiterates: Overweight
Price Target: $8
Current: $5.99
Upside: +33.56%
ADMA Biologics
May 10, 2024
Maintains: Overweight
Price Target: $8$10
Current: $9.56
Upside: +4.60%
Ultragenyx Pharmaceutical
May 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $40.34
Upside: +165.25%
Sarepta Therapeutics
May 2, 2024
Reiterates: Neutral
Price Target: $128
Current: $123.46
Upside: +3.68%
Actinium Pharmaceuticals
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $8.50
Upside: +147.06%
PTC Therapeutics
Apr 12, 2024
Reiterates: Overweight
Price Target: $45
Current: $37.20
Upside: +20.97%
Humacyte
Apr 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $7.15
Upside: -2.10%
Celldex Therapeutics
Mar 22, 2024
Reiterates: Overweight
Price Target: $67
Current: $36.92
Upside: +81.47%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $2$3
Current: $0.91
Upside: +230.58%
Amicus Therapeutics
Feb 29, 2024
Reiterates: Overweight
Price Target: $22
Current: $9.66
Upside: +127.74%
Lineage Cell Therapeutics
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.05
Upside: +471.43%
uniQure
Dec 20, 2023
Reiterates: Overweight
Price Target: $21
Current: $4.76
Upside: +341.18%
Soleno Therapeutics
Sep 26, 2023
Maintains: Overweight
Price Target: $19$35
Current: $41.16
Upside: -14.97%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Neutral
Price Target: $90$20
Current: $7.90
Upside: +153.16%
Alpha Tau Medical
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.53
Upside: +809.09%
Mustang Bio
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.21
Upside: +8,475.51%
Ocuphire Pharma
Aug 14, 2023
Reiterates: Overweight
Price Target: $17
Current: $1.76
Upside: +865.91%
DURECT
Aug 10, 2023
Maintains: Overweight
Price Target: $44$41
Current: $1.30
Upside: +3,053.85%
X4 Pharmaceuticals
Mar 22, 2023
Maintains: Overweight
Price Target: $3
Current: $0.90
Upside: +232.19%
Galecto
Mar 17, 2023
Initiates: Overweight
Price Target: $16
Current: $0.63
Upside: +2,440.09%
iBio, Inc.
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250$85
Current: $2.19
Upside: +3,781.28%
Hepion Pharmaceuticals
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $1.12
Upside: +6,150.00%
Evelo Biosciences
Jun 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.00
Upside: -
Chemomab Therapeutics
May 26, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.87
Upside: -
Ocugen
May 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Marker Therapeutics
Mar 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.14
Upside: -
Evogene
Dec 1, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Galmed Pharmaceuticals
Jan 30, 2020
Assumes: Overweight
Price Target: n/a
Current: $0.39
Upside: -
BiomX
Jan 9, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.34
Upside: -